#USA #New York #Securities Fraud #Pomerantz #Altimmune

Pomerantz Law Firm Investigates Altimmune, Inc. on Behalf of Investors

Pomerantz Law Firm has launched an investigation into Altimmune, Inc. (NASDAQ: ALT) to explore claims of alleged securities fraud. This comes in the wake of a substantial decline in Altimmune's stock price following the announcement of trial results from their recent clinical studies.

On June 26, 2025, Altimmune released a press statement detailing the topline results from the IMPACT Phase 2b trial regarding pemvidutide, a treatment for metabolic dysfunction-associated steatohepatitis (MASH). While the company labeled the results as "positive," they also contained crucial data that showed only minor improvements in fibrosis without worsening MASH when compared to a placebo. Specifically, the efficacy indicators reflected that 31.8% and 34.5% of patients achieved fibrosis improvement with dosages of 1.2 mg and 1.8 mg of pemvidutide, respectively, versus 25.9% for the placebo group. However, these differences were not statistically significant.

The market reacted swiftly to this announcement, leading to an alarming drop in Altimmune's stock price, which fell by $4.10, equating to a drastic 53.18% decrease, closing at $3.61 per share the same day. This sudden plunge prompted concern among investors, many of whom are now questioning the transparency of the company's communications regarding trial outcomes and overall business practices.

Pomerantz LLP, known for its expertise in securities and antitrust litigation, is urging any investors affected by this recent turn of events to reach out for consultation. The firm has a long-standing reputation, having been established by Abraham L. Pomerantz, a pioneer in the field of securities class actions. The firm prides itself on advocating for the rights of victims of corporate misconduct and securities fraud, having secured substantial financial recoveries for class members over its more than 85-year history.

Those who believe they may have been misled in their investments concerning Altimmune are encouraged to contact Danielle Peyton at [email protected] or via phone at 646-581-9980, extension 7980. Additionally, the firm has set up a link for investors interested in joining a potential class action lawsuit against Altimmune.

As the investigation unfolds, it will determine whether Altimmune's leadership, including its officers and directors, may have engaged in unlawful business practices affecting their investors. Stakeholders are closely monitoring developments as the implications of these findings could significantly impact both Altimmune's operational strategies moving forward and the financial outcomes for its investors.

For more information about Pomerantz LLP and their ongoing investigation into Altimmune, please visit their official website. Keeping abreast of this situation is vital for investors who are invested in Altimmune or consider future investments in the biotechnology sector, especially as it pertains to public disclosures and the expected performance of clinical trials. The outcome could set precedence in the field of investor protection and corporate accountability.